[{"id":"8b53a2b0-726f-488a-ad4e-487b5d2d48cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04895761","created_at":"2021-05-20T11:54:08.701Z","updated_at":"2024-07-02T16:35:22.223Z","phase":"Phase 1","brief_title":"Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer","source_id_and_acronym":"NCT04895761","lead_sponsor":"Providence Health \u0026 Services","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HER-2 expression • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • letrozole • maveropepimut-S (MVP-S) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 09/10/2021","start_date":" 09/10/2021","primary_txt":" Primary completion: 06/16/2023","primary_completion_date":" 06/16/2023","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-01-25"},{"id":"5299d983-b5a6-4139-a880-c383cdcdadb8","acronym":"SPiReL","url":"https://clinicaltrials.gov/study/NCT03349450","created_at":"2021-01-18T16:32:24.143Z","updated_at":"2025-02-25T16:07:12.338Z","phase":"Phase 2","brief_title":"DPX-Survivac and Checkpoint Inhibitor in DLBCL","source_id_and_acronym":"NCT03349450 - SPiReL","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" BIRC5","pipe":" | ","alterations":" BIRC5 expression","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BIRC5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/13/2018","start_date":" 03/13/2018","primary_txt":" Primary completion: 10/31/2021","primary_completion_date":" 10/31/2021","study_txt":" Completion: 07/18/2023","study_completion_date":" 07/18/2023","last_update_posted":"2023-11-02"},{"id":"39fb3a40-1da6-4a5f-a51a-d270235ef673","acronym":"VITALIZE","url":"https://clinicaltrials.gov/study/NCT04920617","created_at":"2021-06-11T00:54:35.677Z","updated_at":"2025-02-25T16:16:21.527Z","phase":"Phase 2b","brief_title":"DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04920617 - VITALIZE","lead_sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/18/2021","start_date":" 06/18/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2023-04-07"},{"id":"7d618474-6245-4ce7-a481-a42d155c55d0","acronym":"KEYNOTE 903","url":"https://clinicaltrials.gov/study/NCT03836352","created_at":"2021-01-17T17:21:32.990Z","updated_at":"2025-02-25T16:08:54.319Z","phase":"Phase 2","brief_title":"Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide \u0026 Pembrolizumab, in Subjects With Selected Advanced \u0026 Recurrent Solid Tumors","source_id_and_acronym":"NCT03836352 - KEYNOTE 903","lead_sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • maveropepimut-S (MVP-S) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-03-31"},{"id":"b35e4385-5542-41cd-ab43-a9571f86de15","acronym":"","url":"https://clinicaltrials.gov/study/NCT01416038","created_at":"2021-01-18T05:49:49.052Z","updated_at":"2024-07-02T16:37:23.200Z","phase":"Phase 1","brief_title":"Phase 1 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer","source_id_and_acronym":"NCT01416038","lead_sponsor":"ImmunoVaccine Technologies, Inc. (IMV Inc.)","biomarkers":" BIRC5","pipe":"","alterations":" ","tags":["BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • maveropepimut-S (MVP-S) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 12/01/2011","start_date":" 12/01/2011","primary_txt":" Primary completion: 05/01/2013","primary_completion_date":" 05/01/2013","study_txt":" Completion: 05/01/2013","study_completion_date":" 05/01/2013","last_update_posted":"2017-04-21"}]